These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
448 related articles for article (PubMed ID: 25060056)
1. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. Lewis JB; Sika M; Koury MJ; Chuang P; Schulman G; Smith MT; Whittier FC; Linfert DR; Galphin CM; Athreya BP; Nossuli AK; Chang IJ; Blumenthal SS; Manley J; Zeig S; Kant KS; Olivero JJ; Greene T; Dwyer JP; J Am Soc Nephrol; 2015 Feb; 26(2):493-503. PubMed ID: 25060056 [TBL] [Abstract][Full Text] [Related]
2. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial. Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE; Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079 [TBL] [Abstract][Full Text] [Related]
3. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5. Block GA; Fishbane S; Rodriguez M; Smits G; Shemesh S; Pergola PE; Wolf M; Chertow GM Am J Kidney Dis; 2015 May; 65(5):728-36. PubMed ID: 25468387 [TBL] [Abstract][Full Text] [Related]
4. Role of Ferric Citrate in Hyperphosphatemia and Iron Deficiency Anemia in Non Dialysis CKD Patients. Nand N; Giri K; Jain D J Assoc Physicians India; 2019 Apr; 67(4):53-56. PubMed ID: 31311220 [TBL] [Abstract][Full Text] [Related]
5. Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD. Umanath K; Jalal DI; Greco BA; Umeukeje EM; Reisin E; Manley J; Zeig S; Negoi DG; Hiremath AN; Blumenthal SS; Sika M; Niecestro R; Koury MJ; Ma KN; Greene T; Lewis JB; Dwyer JP; J Am Soc Nephrol; 2015 Oct; 26(10):2578-87. PubMed ID: 25736045 [TBL] [Abstract][Full Text] [Related]
6. Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Umanath K; Sika M; Niecestro R; Connelly C; Schulman G; Koury MJ; Lewis JB; Dwyer JP; Hemodial Int; 2013 Jan; 17(1):67-74. PubMed ID: 22702490 [TBL] [Abstract][Full Text] [Related]
7. Ferric citrate controls serum phosphorus in dialysis patients: retrospective data . Hain DJ; Marinaro M; Koeper DW; Rosenthal MA; Chillemi S; Huffman JM; Gerbeling T; Pritsiolas JM; Loram LC; Pergola PE Clin Nephrol; 2017 Jul; 88(1):12-18. PubMed ID: 28561732 [TBL] [Abstract][Full Text] [Related]
8. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Dwyer JP; Sika M; Schulman G; Chang IJ; Anger M; Smith M; Kaplan M; Zeig S; Koury MJ; Blumenthal SS; Lewis JB; Am J Kidney Dis; 2013 May; 61(5):759-66. PubMed ID: 23369827 [TBL] [Abstract][Full Text] [Related]
9. The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis . Umanath K; Greco B; Jalal DI; McFadden M; Sika M; Koury MJ; Niecestro R; Hunsicker LG; Greene T; Lewis JB; Dwyer JP Clin Nephrol; 2017 Mar; 87 (2017)(3):124-133. PubMed ID: 28128726 [TBL] [Abstract][Full Text] [Related]
10. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Yokoyama K; Hirakata H; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Block GA Clin J Am Soc Nephrol; 2014 Mar; 9(3):543-52. PubMed ID: 24408120 [TBL] [Abstract][Full Text] [Related]
11. Biochemical markers of iron status and iron accumulation in peritoneal dialysis patients treated with ferric citrate. Navarrete JE; Ajiboye O; Lea JI Perit Dial Int; 2024 Mar; 44(2):133-140. PubMed ID: 37691436 [TBL] [Abstract][Full Text] [Related]
12. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study. Lee CT; Wu IW; Chiang SS; Peng YS; Shu KH; Wu MJ; Wu MS J Nephrol; 2015 Feb; 28(1):105-13. PubMed ID: 24840781 [TBL] [Abstract][Full Text] [Related]
13. Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data. Rodby RA; Umanath K; Niecestro R; Bond TC; Sika M; Lewis J; Dwyer JP; Drugs R D; 2015 Sep; 15(3):271-9. PubMed ID: 26239948 [TBL] [Abstract][Full Text] [Related]
14. Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients. Hanudel MR; Laster M; Ramos G; Gales B; Salusky IB Pediatr Nephrol; 2018 Nov; 33(11):2137-2142. PubMed ID: 29956006 [TBL] [Abstract][Full Text] [Related]
15. The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Sinsakul M; Sika M; Koury M; Shapiro W; Greene T; Dwyer J; Smith M; Korbet S; Lewis J; Nephron Clin Pract; 2012; 121(1-2):c25-9. PubMed ID: 23075669 [TBL] [Abstract][Full Text] [Related]
16. Ferric Citrate in Patients With Chronic Kidney Disease. Block GA Semin Nephrol; 2016 Mar; 36(2):130-5. PubMed ID: 27236135 [TBL] [Abstract][Full Text] [Related]
17. A Randomized Trial of the Impact of Ferric Citrate on Erythropoietin and Intravenous Iron Use in Patients Receiving Dialysis. Block GA; Mizani MR; Broumand V; Newby FD; Erinle A; Arias C; Block M; Brillhart S; Leppink A; Danese M; Dittrich M Am J Nephrol; 2024; 55(5):520-528. PubMed ID: 38972306 [TBL] [Abstract][Full Text] [Related]
18. Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial. Womack R; Berru F; Panwar B; Gutiérrez OM Clin J Am Soc Nephrol; 2020 Sep; 15(9):1251-1258. PubMed ID: 32694162 [TBL] [Abstract][Full Text] [Related]
19. A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD. Block GA; Block MS; Smits G; Mehta R; Isakova T; Wolf M; Chertow GM J Am Soc Nephrol; 2019 Aug; 30(8):1495-1504. PubMed ID: 31278194 [TBL] [Abstract][Full Text] [Related]
20. Using iron-based phosphate binders in phosphate reduction and anemia improvement in patients receiving dialysis: a meta-analysis of randomized controlled trials. Zhu Y; Rao J; Liao X; Ou J; Li W; Xue C Int Urol Nephrol; 2021 Sep; 53(9):1899-1909. PubMed ID: 33675476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]